Two Sigma Advisers
XBIO icon

Two Sigma Advisers’s Xenetic Biosciences XBIO Stock Holding History

Two Sigma Advisers’s Portfolio XBIO Stock Details XBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-2,440
Closed -$31K – 2930
2021
Q4 		$31K Sell
2,440
-13,070
-84% -$209K ﹤0.01% 2521
2021
Q3 		$318K Buy
+15,510
New +$423K ﹤0.01% 2092

Other funds holding XBIO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JEST
JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return
JMPWA
JP Morgan Private Wealth Advisors San Francisco, California $35B AUM 24.26% 1-Year Est. Return
SPIA
Steward Partners Investment Advisory New York $19.6B AUM 22.89% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Two Sigma Advisers's XBIO Position: Q1 2022 in Review

Two Sigma Advisers sold out of Xenetic Biosciences (XBIO) in Q1 2022, closing a stake of 2,440 shares — an estimated $31K sold.

Two Sigma Advisers first reported a position in XBIO in Q3 2021 and held it in 2 quarters. The position peaked at $318K in Q3 2021. 14 funds tracked by Wall St. Rank hold XBIO as of Q1 2022.

  • Two Sigma Advisers reported no remaining Xenetic Biosciences position as of Q1 2022 after selling out during the quarter.
  • Two Sigma Advisers sold 2,440 Xenetic Biosciences shares in Q1 2022, an estimated $31K.
  • Two Sigma Advisers first reported a position in Xenetic Biosciences in Q3 2021 and held it in 2 quarters.
  • Two Sigma Advisers's Xenetic Biosciences position peaked at $318K in Q3 2021.
  • 14 funds tracked by Wall St. Rank held Xenetic Biosciences as of Q1 2022.

Based on Two Sigma Advisers's 13F filing for Q1 2022, filed 16 May 2022.